BCL2 and acute myeloid leukemia: In this review, we therefore report on the genetic background associated with treatment response, primary or secondary resistance, as well as overall survival (OS) for the most frequently used new substances in AML treatment, including FLT3 inhibitors, IDH1/2 inhibitors, the BCL-2 inhibitor VEN, hypomethylating agents (HMA), GO and the new liposomal combination chemotherapy CPX-351 (Figure 1).